Department of Endocrinology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, China.
Department of Good Clinical Practice (GCP), The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
Front Cell Infect Microbiol. 2021 Jul 19;11:665406. doi: 10.3389/fcimb.2021.665406. eCollection 2021.
Gut microbiota has been proved to be involved in the occurrence and development of many diseases, such as type 2 diabetes, obesity, coronary heart disease, etcetera. It provides a new idea for the pathogenesis of polycystic ovary syndrome (PCOS). Our study showed that the gut microbial community of PCOS with high low-density lipoprotein cholesterol (LDLC) has a noticeable imbalance. Gut microbiota of PCOS patients was significantly changed compared with CON, and these changes were closely related to LDLC. Gut microbiota may affect the metabolic level of PCOS patients through multiple metabolic pathways, and lipid metabolism disorder may further aggravate the imbalance of gut microbiota. , and had high accuracy in the diagnosis of PCOS and the differentiation of subgroups, suggesting that they may play an important role in the diagnosis and treatment of PCOS in the future. Also, the model we built showed good specificity and sensitivity for distinguishing PCOS from CON (including L_CON and L_PCOS, H_CON and H_PCOS). In conclusion, this is the first report on the gut microbiota of PCOS with high LDLC, suggesting that in the drug development or treatment of PCOS patients, the difference of gut microbiota in PCOS patients with different LDLC levels should be fully considered.
肠道微生物群已被证明与许多疾病的发生和发展有关,如 2 型糖尿病、肥胖、冠心病等。它为多囊卵巢综合征(PCOS)的发病机制提供了新的思路。我们的研究表明,伴有高低密度脂蛋白胆固醇(LDLC)的 PCOS 肠道微生物群落存在明显失衡。与 CON 相比,PCOS 患者的肠道微生物群发生了显著变化,这些变化与 LDLC 密切相关。肠道微生物群可能通过多种代谢途径影响 PCOS 患者的代谢水平,而脂代谢紊乱可能进一步加剧肠道微生物群的失衡。 和 在诊断 PCOS 和亚组分化方面具有较高的准确性,表明它们可能在未来的 PCOS 诊断和治疗中发挥重要作用。此外,我们构建的模型在区分 PCOS 和 CON(包括 L_CON 和 L_PCOS、H_CON 和 H_PCOS)方面表现出良好的特异性和敏感性。总之,这是第一篇关于伴有高 LDLC 的 PCOS 肠道微生物群的报告,表明在开发或治疗 PCOS 患者的药物时,应充分考虑不同 LDLC 水平的 PCOS 患者肠道微生物群的差异。